– Technology to culture effective cells by adjusting cell size and culture environment.
– ‘SMUP-Cell’ technology, demonstrates superior technology in next-generation stem cell culture.
On June 27, MEDIPOST announced that it has obtained a patent on method for culturing mesenchymal stem cells according to cell size in 6 European countries including UK, Germany, France, Italy, Switzerland and Spain.
The tile of this patent is ‘Method for Culturing Mesenchymal Stem Cells According to Cell Size’ and the patent covers an innovative technology that can culture high efficacy of mesenchymal stem cells by adjusting cell size and culture environment.
MEDIPOST expects to apply the patent to a new process in the production of mesenchymal stem cells to mass produce cells with good stem cell function, including proliferation and differentiation.
MEDIPOST already had obtained a similar patent in Korea, Japan and Australia and naming this next-generation stem cell as ‘SMUP-Cell’, MEDIPOST has been running a test production in a GMP facility.
Medipost official said, ” We have demonstrated international superiority in technology for next-generation stem cell culture with this patent”, ” We have now evaluated efficacy and safety of new drugs using this technology as a full-time research.”